Skip to content
S5134Senate2023-2024 SessionSame asA6186

Require Insurers Cover Ovarian Testing

Official title

“Requires health insurance policies to fully cover multi-marker testing related to certain patients”

Sponsor Roxanne J. PersaudSD-19+1 co-sponsorAffects Finance
Status
In Senate Committee
Insurance
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

The bill requires health insurance policies in New York to fully cover multi-marker ovarian cancer testing for patients diagnosed with an ovarian adnexal mass, with no cost to the patient.

Why it matters

  1. Ensures earlier and more accurate detection. By mandating coverage of multi-marker ovarian cancer tests for those with ovarian adnexal masses, the bill seeks to improve early detection and diagnosis, which is critical for patient outcomes and survival rates.

  2. Reduces financial barriers for patients. Prohibiting insurers from requiring deductibles or coinsurance for these tests removes out-of-pocket costs, making advanced diagnostic tools accessible to more patients regardless of income or insurance plan structure.

  3. Promotes equity in healthcare access. The requirements apply broadly to individual, group, and public insurance (including Medicaid), helping to ensure that vulnerable populations and those with lower incomes can benefit from state-of-the-art ovarian cancer testing.

  4. Could influence standards of cancer care. By codifying insurance coverage for specific diagnostic technologies, the bill may encourage wider adoption of multi-marker testing in clinical practice and stimulate further innovation in cancer diagnostics.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients diagnosed with an ovarian adnexal mass

    The bill would require full coverage of ovarian cancer-related multi-marker testing, with insurers bearing the cost rather than applying annual deductibles or coinsurance.

  • Health insurers and health service corporations

    Covered policies would have to offer the testing benefit when issued, reissued, renewed, modified or amended on or after the bill’s effective date.

  • Medicaid beneficiaries with an ovarian adnexal mass

    The bill would add ovarian cancer-related multi-marker testing to covered medical assistance services.

Headline styles

Require Insurers Cover Ovarian Testing

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Roxanne J. Persaud

Senator · Senate District 19

Chair, Social Services

1 Co-sponsor

History

  1. Referred to insurance
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6186Assembly

Require Ovarian Cancer Test Coverage

In Assembly Committee · Insurance · Sponsor Pamela J. Hunter

Impact 6 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5134

2023-2024 Regular Sessions

IN SENATE

February 23, 2023

Introduced by Sen. PERSAUD -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law and the social services law, in relation to requiring health insurance policies to fully cover multimarker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 11-c to read as follows:

(11-c) (A) Every policy that provides coverage for hospital, surgical or medical care shall offer full coverage for multi-marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass.

(B) Such additional coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 11-c to read as follows:

(11-c) (A) Every insurer delivering a group or blanket policy or issuing a group or blanket policy for delivery in this state that provides coverage for hospital, surgical or medical care shall offer full coverage for multi-marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass.

(B) Such additional coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 3. Section 4303 of the insurance law is amended by adding a new subsection (p-1) to read as follows:

(p-1) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation that provides coverage for hospital, surgical or medical care shall offer full coverage for multi-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD07245-01-3

marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass.

(2) Such additional coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 4. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (kk) to read as follows:

(kk) multi-marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass.

§ 5. This act shall take effect on the first of January next succeeding the date on which it shall have become a law and shall apply to policies issued, reissued, renewed, modified or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the social services law, in relation to requiring health insurance policies to fully cover multi- marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass

Purpose

Requires health insurance policies to fully cover multi-marker testing related to certain patients.

Summary of provisions

Section I Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 11-c that requires policies that provide coverage for hospital, surgical or medical care to also provide full coverage for multimarker testing related to ovarian cancer to patients who have been diagnosed with an ovarian adnexal mass.

Subsection (I) of section 3221 of the insurance law is amended by adding a new paragraph 11-c that requires insurers delivering a group or blan- ket policy or issuing a group or blanket policy in this state covering for hospital, surgical or medical care to also provide full coverage for multimarker testing related to ovarian cancer to patients who have been diagnosed with an ovarian adnexal mass.

A medical expense indemnity corporations, hospital service corporations, and health service corporations that provides coverage for hospital, surgical or medical care to also provide full coverage for multimarker testing related to ovarian cancer to patients who have been diagnosed with an ovarian adnexal mass.

Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (kk) that amends definitive language.

Justification

The American Cancer Society finds that ovarian cancer ranks fifth in cancer deaths among women. The gold standard in ovarian detection, the cancer antigen-125 (CA-125) blood test, is useful in treating women known to have the condition but not for screening purposes. Research shows that including additional biomarkers in diagnostic screening improves the early detection of ovarian cancer with a diagnostic power of 86% sensitivity (SN) for early-stage and 93% SN for late-stage ovari- an cancer at 98% specificity (SP) (Yurkovetsky et. al., 2010).

Providing full coverage for multi-marker testing related to ovarian cancer can improve the early detection and treatment outcomes for patients who are diagnosed with this condition. They can also cut unnec- essary spending by $0.05 PMPM (per month per member) (Brodsky et. al. 2017) by preventing false-diagnosis and over-treatment for this condi- tion (Wald et. al., 2022).

Legislative history

New bill.

Fiscal impact on the state

To be determined.

Effective date

This act shall take effect on the first of January next succeeding the date on which it shall have become a law and shall apply to policies issued, reissued, renewed, modified or amended on or after such date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.